These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21426096)

  • 1. Application of emerging toxicity screens in drug discovery: challenges and implications.
    Wilson AG; Liu X; Kramer JA
    Future Med Chem; 2009 Oct; 1(7):1201-5. PubMed ID: 21426096
    [No Abstract]   [Full Text] [Related]  

  • 2. High-throughput human metabolism and toxicity analysis.
    Lee MY; Dordick JS
    Curr Opin Biotechnol; 2006 Dec; 17(6):619-27. PubMed ID: 17046235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADMET--Fifth Annual SMi Conference.
    Comer JE
    IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC; McPate MJ; El Harchi A; Zhang YH
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
    Gintant GA
    Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single dose toxicity and repeated dose toxicity studies: introductory remarks.
    Kurokawa Y; Matsuzawa T
    J Toxicol Sci; 1996 Dec; 21(5):413-6. PubMed ID: 9035047
    [No Abstract]   [Full Text] [Related]  

  • 9. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM
    Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
    Stevens JL
    Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds.
    Wu Y; Connors D; Barber L; Jayachandra S; Hanumegowda UM; Adams SP
    Toxicol In Vitro; 2009 Sep; 23(6):1170-8. PubMed ID: 19523510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whither the resolution of testicular toxicity?
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):504-7. PubMed ID: 21770029
    [No Abstract]   [Full Text] [Related]  

  • 13. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on incidence and nature of testicular toxicity findings in pharmaceutical development survey: a pathologist's perspective.
    Creasy DM
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):508-10. PubMed ID: 21818841
    [No Abstract]   [Full Text] [Related]  

  • 15. Building predictive ADMET models for early decisions in drug discovery.
    Penzotti JE; Landrum GA; Putta S
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on "incidence and nature of testicular toxicity findings…".
    Boekelheide K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):501-3. PubMed ID: 21948622
    [No Abstract]   [Full Text] [Related]  

  • 17. High-throughput assay development for combined in vitro toxicity screening of hit compounds and their metabolites in early drug-discovery stage.
    Siricilla S
    Bioanalysis; 2017 Jul; 9(13):959-961. PubMed ID: 28708435
    [No Abstract]   [Full Text] [Related]  

  • 18. The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development.
    Ball SE; Scatina JA; Sisenwine SF; Fisher GL
    Drug Chem Toxicol; 1995 Feb; 18(1):1-28. PubMed ID: 7768197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organotypic systems in drug metabolism and toxicity: challenges and opportunities.
    Dash A; Blackman BR; Wamhoff BR
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):999-1014. PubMed ID: 22632603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding mechanisms of toxicity: insights from drug discovery research.
    Houck KA; Kavlock RJ
    Toxicol Appl Pharmacol; 2008 Mar; 227(2):163-78. PubMed ID: 18063003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.